ID: 1072 Increasing dose of intravenous human adipose-derived stem cells improves the pancreatic function of diabetic mice

Authors

  • Loan Thi-Tung Dang Laboratory of Stem Cell Research and Application, University of Science, Vietnam National University HCMC, Ho Chi Minh City, Vietnam
  • Anh Nguyen Tu Bui Laboratory of Stem Cell Research and Application, University of Science, Vietnam National University HCMC, Ho Chi Minh City, Vietnam
  • Cong Le Thanh Nguyen Laboratory of Stem Cell Research and Application, University of Science, Vietnam National University HCMC, Ho Chi Minh City, Vietnam
  • Nhat Chau Truong Laboratory of Stem Cell Research and Application, University of Science, Vietnam National University, Ho Chi Minh city Viet Nam
  • Anh Thi Van Bui Laboratory of Stem Cell Research and Application, University of Science, Vietnam National University HCMC, Ho Chi Minh City, Vietnam
  • Ngoc Kim Phan Laboratory of Stem Cell Research and Application, University of Science, Vietnam National University HCMC, Ho Chi Minh City, Vietnam
  • Kiet Dinh Truong Laboratory of Stem Cell Research and Application, University of Science, Vietnam National University HCMC, Ho Chi Minh City, Vietnam
  • Phuc Van Pham Laboratory of Stem Cell Research and Application, University of Science, Vietnam National University HCMC, Ho Chi Minh City, Vietnam

DOI:

https://doi.org/10.15419/bmrat.v4iS.346

Keywords:

Diabetes, dose, stem cell, streptozotocin, Regenerative Medicine

Abstract

Mesenchymal tem cell transplantation is a novel treatment for diabetes mellitus, especially type 1 diabetes. Many publications have proved the effect of MSC therapy on reducing blood glucose and improving insulin production in type 1 diabetic animal as well as in clinic trials. However, there is no conclusion that how many cells are effective for diabetes. Thus, this study has investigated that different adipose-derived MSC doses affected glucose metabolism in diabetic mice. STZ-induced diabetic mice were intravenous transfused with human MSCs with dose either 106 (treated group A) or 2x106 cells/mouse (treated group B). Both treated and untreated mice were monitored the blood glucose levels, glucose and insulin tolerance test, pancreatic structure change and insulin production every week until 56 days after transplantation. The results showed that the higher dose of MSC could reduce death rate (66% vs. 0% death in group A vs. group B after 56 days of treatment, respectively) and remarkably lower blood glucose levels while the mice treated with 1x106 cells/dose remaining hyperglycemia. Moreover, the glucose tolerance and insulin tolerance as well as insulin production were improved in group B at 28 days after transplantation. The histochemical imaging further demonstrated the decrease of inflammatory cells in the islets and the restoration of pancreatic structures in higher-dose-MSCs-treated mice. Thus, the dose 2x106 cells of MSCs may be an effective strategy for diabetes mellitus concerning hyperglycemia, impaired glucose metabolism and islet destruction.

References

1. Ezquer, F. E., et al. (2008). "Systemic administration of multipotent mesenchymal stromal cells reverts hyperglycemia and prevents nephropathy in type 1 diabetic mice." Biol Blood Marrow Transplant 14(6): 631-640.
2. Gao, F., et al. (2016). "Mesenchymal stem cells and immunomodulation: current status and future prospects." Cell Death Dis 7: e2062.
3. Kono, T. M., et al. (2014). "Human adipose-derived stromal/stem cells protect against STZ-induced hyperglycemia: analysis of hASC-derived paracrine effectors." Stem Cells 32(7): 1831-1842.

Downloads

Published

2017-09-05

How to Cite

ID: 1072 Increasing dose of intravenous human adipose-derived stem cells improves the pancreatic function of diabetic mice. (2017). Biomedical Research and Therapy, 4(S), S 154-155. https://doi.org/10.15419/bmrat.v4iS.346

Similar Articles

1-10 of 611

You may also start an advanced similarity search for this article.